Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cephalon Makes A $130 Mil. Bet On Australian Mesoblast's Stem Cell Technology

This article was originally published in PharmAsia News

Executive Summary

Cephalon is making a significant bet on an Australian biotech's adult stem cell technology, taking it forward in multiple indications, including some fields where it isn't currently active, but which its executives say it can get up to speed on quickly. The deal is the specialty pharma company's fourth in biologics since it announced nearly two years ago that expanding into biologics would be a priority

You may also be interested in...

Mesoblast/Teva May Have Shorter Path To Market In Chronic Heart Failure

Now studying stem-cell candidate MPC-150-IM in two 600-patient Phase III trials in advanced heart failure, the partners could complete the Phase III program more quickly and less expensively.

Mesoblast Sees Chance For Faster Phase III Heart Failure Trial

The Australian stem cell company said a Phase III trial being run by partner Teva and testing MPC-150-IM in chronic heart failure could finish earlier than expected because of an interim superiority analysis.

Australian Stem Cell Company Mesoblast To Get AU$170 Million Private Placement As Clinical Trials Ramp Up

Mesoblast Ltd., which Teva holds a 20% stake in, aims to raise AU$170 million by issuing new shares to a select group of existing and new global institutional investors.

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts